Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Cancer Lett. 2015 Oct 22;370(1):78–84. doi: 10.1016/j.canlet.2015.09.020

Fig. 1.

Fig. 1

Major multimodal strategies for RFA-combined therapies of HCCs. Combination of RFA with TACE and PEI has been established as a clinical strategy for treating HCC, while Sorafenib and Nano-drug (ThermoDox®) have entered Phase III clinical trial stage in combination with RFA. Combination of RFA with immunotherapy is still in preclinical stage.